Podcast Episodes
Back to Search
Ep. 356 - Arrowhead’s arc. Plus: AI in biotech venture, Synnovation, MFN
Season 7 Episode 356
After 20 years of platform building and resets, Arrowhead Pharmaceuticals is making a bid to become a large-cap biotech. On the latest BioCentury Thi…
5 months, 2 weeks ago
Ep. 355 - Capital market mood, Xenon data, Friedreich ataxia pipeline
Season 7 Episode 355
Biotechs have been pricing follow-ons at a steady pace, with some companies parlaying data into upsized deals, and others even beginning to debut on …
5 months, 3 weeks ago
Ep. 354 - East-West Summit Takeaways
Season 7 Episode 354
Biotechs in South Korea and other regions of Asia outside of China need to lean into innovation to distinguish themselves from their Chinese counterp…
5 months, 3 weeks ago
Ep. 353 - Prasad Departure and Future of Fibrosis Therapies
Season 7 Episode 353
The second ousting of Vinay Prasad from FDA in the past eight months won’t lead to major changes at the agency, other than selecting a successor task…
5 months, 4 weeks ago
Ep. 352 - A Multipolar Biopharma World; Rare Disease Spotlight
Season 7 Episode 352
Can a strong U.S. biopharma industry be reconciled with the successful emergence of China? And can China be a catalyst of positive change across the …
6 months ago
Ep. 351 - Gilead's Arcellx Buy. Plus: ctDNA as Surrogate Endpoint
Season 7 Episode 351
Gilead is acquiring Arcellx for $7.8 billion up front three years after forging a partnership with the biotech around a cell therapy for multiple mye…
6 months, 2 weeks ago
Ep. 350 - Oral SERD Spotlight. Plus: Setbacks at FDA
Season 7 Episode 350
As targeted protein degradation gains momentum, oral selective estrogen receptor degraders are emerging as one of its most advanced proving grounds. …
6 months, 3 weeks ago
Ep. 349 - Start-up Spotlight, Compounding Wegovy & Neuropysch
Season 7 Episode 349
2025 marked the end of a four-year slide in series A financings for biotechs, with 144 biotechs raising an aggregate of $8 billion, up $1 billion fro…
6 months, 4 weeks ago
Ep. 348 - Biotech's 2026 Catalysts. Plus: China's New Orphan Rules
Season 7 Episode 348
RNAi and exon-skipping therapies headline the list of regulatory and pivotal data catalysts in 2026, while new lipid-lowering mechanisms, modalities,…
7 months ago
Ep. 347 - Speeding China's Innovation. Plus: Neuro Catalysts and Newcos
Season 7 Episode 347
New rules in China will accelerate the country’s cell and gene therapy sector by reshaping how investigator-initiated trials are conducted and commer…
7 months, 1 week ago